Cavrotolimod

N/A

Report date: 2025/03/19 14:45:51
NME

Base Information

Drug NameCavrotolimod
Drug Alias NameAST-008
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionToll like receptor 9 agonists
TargetsToll like receptor 9
Therapy Area/IndicationsSolid tumoursSquamous Cell Carcinoma of Head and NeckCarcinoma, Squamous Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineTaiwan +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesExicure Inc
China Registration ClassN/A

Develop Information

Active CompaniesBluejay Therapeutics Inc
Inactive CompaniesExicure Inc
Active IndicationsHepatitis B, Chronic
Inactive IndicationsSolid tumoursSquamous Cell Carcinoma of Head and NeckCarcinoma, Squamous Cell +[5] 

Other Information

ATC CodeN/A
Related LinksN/A